Abstract
A-69024 HBr, 1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4- tetrahydroisoquinoline hydrobromide, is a selective antagonist of the dopamine D-1 receptor. A-69024 HBr shows an apparent affinity toward the D-1 receptor (identified using [125I]SCH 23390) of 12.6 (4.15-38.3) nM (mean (90% CL), n = 3); the apparent affinity toward the D-2 receptor (identified using [3H]spiroperidol is 1 290 (1,200-1,380) nM (n = 3); using [125I]lysergic acid diethylamine to identify the 5-HT1C receptor gives apparent affinity of 17,800 (9,700-32,600) nM (n = 3). In assays of adenylate cyclase activity, A-69024 HBr antagonizes the D-1 receptor with a calculated affinity of 43.9 (17.5-110) nM (n = 5), while the molecule antagonizes the D-2 receptor with a calculated affinity greater than 400 nM. Behavioral studies demonstrate that A-69024 HBr (5 mg/kg s.c.) is able to block both amphetamine-induced locomotor activity and apomorphine-induced stereotypy. Furthermore, A-69024 HBr blocks SF&F 38393-, but not quinpirole-, induced rotation in rats having unilateral 6-hydroxydopamine lesions of the substantia nigra. When administered at behaviorally effective doses. A-69024 HBr neither increases the concentration of serum prolactin nor ...Continue Reading
References
Dec 29, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Walters, R H Roth
Apr 1, 1978·Journal of Molecular and Cellular Cardiology·G I Drummond, J Dunham
Jan 11, 1979·Nature·J W Kebabian, D B Calne
Apr 18, 1979·Biochimica Et Biophysica Acta·J J de PontS L Bonting
Jan 1, 1985·Psychopharmacology·J Arnt, J Hyttel
Nov 5, 1985·European Journal of Pharmacology·M Morelli, G Di Chiara
Jan 14, 1986·European Journal of Pharmacology·P H AndersenC Braestrup
Jun 9, 1986·Life Sciences·K E FlaimJ Weinstock
Jan 1, 1987·Synapse·P Seeman
Jul 31, 1985·European Journal of Pharmacology·A Sidhu, J W Kebabian
Dec 1, 1986·Journal of Neurochemistry·P H Andersen, C Braestrup
Sep 9, 1986·European Journal of Pharmacology·A SidhuJ W Kebabian
Jan 1, 1987·Synapse·D Clark, F J White
Jan 1, 1988·Journal of Neural Transmission·P DostertG Dordain
Oct 1, 1988·Journal of Medicinal Chemistry·P S CharifsonR B Mailman
May 20, 1988·European Journal of Pharmacology·D Hoyer, A Karpf
Dec 1, 1973·Biochemical Pharmacology·Y Cheng, W H Prusoff
Aug 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·J W KebabianP Greengard
Apr 16, 1984·Life Sciences·A V ChristensenO Svendsen
Jul 15, 1983·European Journal of Pharmacology·J Hyttel
Aug 1, 1983·Journal of Medicinal Chemistry·R D TitusM M Foreman
Mar 1, 1982·Endocrinology·T E CoteJ W Kebabian
Jun 1, 1982·Endocrinology·E A FreyJ W Kebabian
Citations
Jan 1, 1996·Journal of Neural Transmission·R MarksteinD Hoyer
Jan 1, 1995·Journal of Neural Transmission. General Section·S C CheethamD J Heal
Jan 1, 1991·Psychopharmacology·T S ShippenbergA Herz
Jan 1, 1992·Psychopharmacology·J HietalaE Syvälahti
Feb 1, 1995·Psychopharmacology·K K GnanalinghamC D Marsden
Jun 25, 1991·European Journal of Pharmacology·M P DeNinnoL Bednarz
Jan 21, 1992·European Journal of Pharmacology·D R Riddall
Jan 14, 1992·European Journal of Pharmacology·J LappalainenE Syvälahti
Mar 24, 1992·European Journal of Pharmacology·S A Daly, J L Waddington
Aug 1, 1991·Pharmacology, Biochemistry, and Behavior·D R BrittonD Kerkman
Mar 1, 1992·Neurochemistry International·S A Daly, J L Waddington
Mar 1, 1992·Neurochemistry International·J W KebabianK E Asin
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·G R BreeseR A Mueller
Dec 1, 1993·Schizophrenia Research·A ZaretskyX Fornazzari
Feb 1, 1995·Nuclear Medicine and Biology·M KassiouR F Dannals
Apr 4, 2002·Nuclear Medicine and Biology·Michael KassiouBernard Maziere
Nov 13, 2008·PloS One·Uri Yerushalmi, Mina Teicher
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Olaf PranteAshutosh Banerjee
Jun 16, 2001·Bioorganic & Medicinal Chemistry·G M CingolaniF Claudi
May 23, 1997·Journal of Medicinal Chemistry·M R MichaelidesK Shiosaki